tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hypertension D006973 115 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Glomerulosclerosis, Focal Segmental D005923 4 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Dermatitis D003872 30 associated lipids
Gastrointestinal Diseases D005767 20 associated lipids
Vomiting D014839 21 associated lipids
Hypersensitivity, Immediate D006969 14 associated lipids
Subarachnoid Hemorrhage D013345 17 associated lipids
Pharyngitis D010612 2 associated lipids
Shock D012769 11 associated lipids
Erythema D004890 22 associated lipids
Dermatomycoses D003881 17 associated lipids
Hyperalgesia D006930 42 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Cholelithiasis D002769 16 associated lipids
Fever D005334 35 associated lipids
Amenorrhea D000568 4 associated lipids
Dermatitis, Seborrheic D012628 10 associated lipids
Thrombocytopenia D013921 15 associated lipids
Hyperlipidemias D006949 73 associated lipids
Shock, Septic D012772 11 associated lipids
Ileal Neoplasms D007078 2 associated lipids
Cough D003371 19 associated lipids
Paraproteinemias D010265 2 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Translocation, Genetic D014178 20 associated lipids
Catalepsy D002375 30 associated lipids
Dermatitis, Atopic D003876 19 associated lipids
Ovarian Cysts D010048 4 associated lipids
Precursor Cell Lymphoblastic Leukemia-Lymphoma D054198 10 associated lipids
Cardiomegaly D006332 31 associated lipids
Hypertension, Renal D006977 9 associated lipids
Metaplasia D008679 7 associated lipids
Burkitt Lymphoma D002051 15 associated lipids
Leukemia, T-Cell D015458 23 associated lipids
Tachycardia D013610 7 associated lipids
Cicatrix D002921 9 associated lipids
Neutropenia D009503 15 associated lipids
Peritoneal Neoplasms D010534 16 associated lipids
Arthritis, Juvenile D001171 8 associated lipids
Urticaria D014581 13 associated lipids
Behcet Syndrome D001528 7 associated lipids
Fetal Hypoxia D005311 3 associated lipids
Thrombophlebitis D013924 6 associated lipids
Cardiomyopathy, Hypertrophic D002312 6 associated lipids
HIV Seropositivity D006679 15 associated lipids
Uveitis D014605 14 associated lipids
Enterobacteriaceae Infections D004756 5 associated lipids
Alveolar Bone Loss D016301 10 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Thomas J et al. The immunosuppressive action of FK506. In vitro induction of allogeneic unresponsiveness in human CTL precursors. 1990 Transplantation pmid:1689518
Vathsala A et al. Analysis of the interactions of immunosuppressive drugs with cyclosporine in inhibiting DNA proliferation. 1990 Transplantation pmid:1689520
McCune TR et al. Effects of tacrolimus on hyperlipidemia after successful renal transplantation: a Southeastern Organ Procurement Foundation multicenter clinical study. 1998 Transplantation pmid:9448150
Mentzer RM et al. Tacrolimus as a rescue immunosuppressant after heart and lung transplantation. The U.S. Multicenter FK506 Study Group. 1998 Transplantation pmid:9448154
Burroughs TE et al. Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. 2007 Transplantation pmid:17452891
First MR Transplantation in the nineties. 1992 Transplantation pmid:1370734
Méndez A et al. Pharmacokinetic study of conversion from tacrolimus twice-daily to tacrolimus once-daily in stable lung transplantation. 2014 Transplantation pmid:24492423
Misra S et al. Red cell aplasia in children on tacrolimus after liver transplantation. 1998 Transplantation pmid:9500636
Hougardy JM et al. The once-daily formulation of tacrolimus: a step forward in kidney transplantation? 2012 Transplantation pmid:22234346
D'Antiga L et al. Late cellular rejection in paediatric liver transplantation: aetiology and outcome. 2002 Transplantation pmid:11792983
Butani L et al. Effect of felodipine on tacrolimus pharmacokinetics in a renal transplant recipient. 2002 Transplantation pmid:11793001
Ferraris JR et al. Conversion from cyclosporine A to tacrolimus in pediatric kidney transplant recipients with chronic rejection: changes in the immune responses. 2004 Transplantation pmid:15084930
Shapiro R et al. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. 1999 Transplantation pmid:10628763
Velidedeoglu E et al. Early kidney dysfunction post liver transplantation predicts late chronic kidney disease. 2004 Transplantation pmid:15084934
Leung W et al. Long-term complete remission and immune tolerance after intensive chemotherapy for lymphoproliferative disorders complicating liver transplant. 1999 Transplantation pmid:10385092
Andrés A et al. A randomized trial comparing renal function in older kidney transplant patients following delayed versus immediate tacrolimus administration. 2009 Transplantation pmid:19898206
Guo Z et al. In vivo effects of leflunomide on normal pancreatic islet and syngeneic islet graft function. 1997 Transplantation pmid:9075844
Xu X et al. FKBP12 is the only FK506 binding protein mediating T-cell inhibition by the immunosuppressant FK506. 2002 Transplantation pmid:12085010
Mueller AR et al. Neurotoxicity after orthotopic liver transplantation. A comparison between cyclosporine and FK506. 1994 Transplantation pmid:7518974
Platz KP et al. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. 1994 Transplantation pmid:7518975
Takaya S et al. Liver transplantation in positive cytotoxic crossmatch cases using FK506, high-dose steroids, and prostaglandin E1. 1992 Transplantation pmid:1279851
Wasik M et al. Effect of FK506 versus cyclosporine on human natural and antibody-dependent cytotoxicity reactions in vitro. 1991 Transplantation pmid:1702910
Carroll PB et al. Effect of the immunosuppressant FK506 on glucose-induced insulin secretion from adult rat islets of Langerhans. 1991 Transplantation pmid:1702911
Sarwal MM et al. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. 2001 Transplantation pmid:11468528
Nobori S et al. Long-term acceptance of fully allogeneic cardiac grafts by cotransplantation of vascularized thymus in miniature swine. 2006 Transplantation pmid:16421473
Luan FL et al. New-onset diabetes mellitus in kidney transplant recipients discharged on steroid-free immunosuppression. 2011 Transplantation pmid:21242885
Takatsuki M et al. Weaning of immunosuppression in living donor liver transplant recipients. 2001 Transplantation pmid:11502975
Shapiro R et al. Alemtuzumab preconditioning with tacrolimus monotherapy-the impact of serial monitoring for donor-specific antibody. 2008 Transplantation pmid:18431232
Meier M et al. Slowing the progression of chronic allograft nephropathy by conversion from cyclosporine to tacrolimus: a randomized controlled trial. 2006 Transplantation pmid:16612281
Iwata H et al. Suppression of allograft responses by combining donor alloantigen-specific intravenous presensitization with suboptimal doses of FK506. 1993 Transplantation pmid:7687396
Panz VR et al. Diabetogenic effect of tacrolimus in South African patients undergoing kidney transplantation1. 2002 Transplantation pmid:11889436
Charney DA et al. Plasma cell-rich acute renal allograft rejection. 1999 Transplantation pmid:10515379
Fisher NC et al. The clinical impact of nephrotoxicity in liver transplantation. 2000 Transplantation pmid:10910259
Brunet M et al. Sequential determination of pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients treated with mycophenolate mofetil. 2006 Transplantation pmid:16495801
Kessler L et al. Tacrolimus-associated optic neuropathy after pancreatic islet transplantation using a sirolimus/tacrolimus immunosuppressive regimen. 2006 Transplantation pmid:16495816
Moffatt SD and Metcalfe SM Comparison between tacrolimus and cyclosporine as immunosuppressive agents compatible with tolerance induction by CD4/CD8 blockade. 2000 Transplantation pmid:10836388
Randhawa PS et al. Clinical significance of renal biopsies showing concurrent acute rejection and tacrolimus-associated tubular vacuolization. 1999 Transplantation pmid:9921801
Meiser BM The best dosing for initial tacrolimus application is trough level adapted! 2005 Transplantation pmid:15714162
Hougardy JM et al. Conversion from Prograf to Advagraf among kidney transplant recipients results in sustained decrease in tacrolimus exposure. 2011 Transplantation pmid:21192316
Ochiai T et al. Studies of the effects of FK506 on renal allografting in the beagle dog. 1987 Transplantation pmid:2447688
Ochiai T et al. Studies of the induction and maintenance of long-term graft acceptance by treatment with FK506 in heterotopic cardiac allotransplantation in rats. 1987 Transplantation pmid:2447689
Bayés B et al. Adiponectin and risk of new-onset diabetes mellitus after kidney transplantation. 2004 Transplantation pmid:15257035
Miao G et al. Development of donor-specific immunoregulatory T-cells after local CTLA4Ig gene transfer to pancreatic allograft. 2004 Transplantation pmid:15257039
Wang X et al. Immunosuppression with a combination of pg490-88 and a subtherapeutic dose of FK506 in a canine renal allograft model. 2005 Transplantation pmid:15940043
Bendahan J et al. The effect of administration of FK506 on delayed regeneration in flushed partially hepatectomized livers. 1994 Transplantation pmid:7511255
Chavin KD et al. Anti-CD2 monoclonal antibodies synergize with FK506 but not with cyclosporine or rapamycin to induce tolerance. 1994 Transplantation pmid:7511258
Ricordi C et al. In vivo effect of FK506 on human pancreatic islets. 1991 Transplantation pmid:1716797
Wiesner RH A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group. 1998 Transplantation pmid:9734494
Chan L et al. Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. 2010 Transplantation pmid:20517177
Hodak SP et al. QT prolongation and near fatal cardiac arrhythmia after intravenous tacrolimus administration: a case report. 1998 Transplantation pmid:9734501